Angle Plc is poised to revolutionise cancer treatment with its Parsortix system, here we catch up with chief executive Andrew Newland. As Newland explains Parsortix can capture cancer cells from blood, which is very significant for the emerging field of personalised medicine as it enables tests for specific cancer cells and means doctors can ensure the right treatment is administered to the patient. Following the release of ANGLE’s financial results Newland reflects on what he calls “an incredible year” and he also discusses first commercial sales, a stream of ‘excellent published evidence’ from third parties and the start of major patient studies. “We’ve got a 200 patient study in Europe running with four big cancer centres … and we’ve just recently announced a similar study in the United States,” he added. Newland says these are substantial trials and, depending upon patient accrual, he expects results from the European study by the end of this calendar year with the US results following a few months after that.
ANGLE PLC (LON:AGL) has signed a contract with the University of Manchester through Cancer Research UK that will see its breakthrough liquid biopsy system Parsortix used in research trials.
Andrew Newland, chief executive, tells Proactive Investors: “This is really important. It comes after four years of working to develop the tests and on the strength of that data they [the University of Manchester] now want to incorporate it for routine use in their clinical laboratory.”
He says Parsortix is already being used in 10 clinical trials, and that the deal is with “one of the foremost customers that we could possibly hope for,” adding that this should give the rest of the market confidence, and “turbocharge” its sales in research use.
Andrew Newland, CEO at Angle PLC, joined us in the Master Investor Show, to share how their patented product, an engineering technology with a profound medical system which is set to tap in the cancer detecting market – fast growing and high value. Interviewed by Zak Mir, Host, Tip TV.
An American study has raised the prospect of a new UK-developed blood test taking the place of painful biopsies in metastatic breast cancer.
The University of Southern California (USC) Norris Comprehensive Cancer Center has been working with the Parsortix device, developed by AIM-listed ANGLE PLC (LON:AGL), to harvest circulating tumour cells
Andrew Newland, chief executive of specialist med-tech company ANGLE plc (LON:AGL), believes the company’s Parsortix liquid biopsy could be a “real game-changer” in the battle against prostate cancer.
Data from a Barts Cancer Institute study suggested that the Parsortix system can not only detect the disease, but can also identify how aggressive it is.
Although Newland believes Parsortix will need at least 18 months of further research, he says he’s well aware that “there’s a tremendous opportunity here commercially”.
ANGLE (LON:AGL) chief executive Andrew Newland says the high quality evidence backing up the effectiveness of the company’s Parsortix system is a major driver in terms of its future commercial potential.
Andrew Newland, founder and chief executive of ANGLE plc (LON:AGL), comments on the publication of the first peer-reviewed paper of Parsortix in a journal by Barts Cancer Institute, one of ANGLE’s key opinion leaders.
They assessed the device’s ability to pick up signs of prostate cancer from blood samples and found Partsortix to be superior in many ways to the current gold standard – antibody-based detection.
30 July 2015: ANGLE plc chief executive Andrew Newland tells IG that the company is making excellent progress with its Parsortix cell separation system. Now working with nine key opinion leaders to develop a pipeline.
The chief executive of Angle plc (LON:AGL), Andrew Newland, says the company hit all of its significant milestones effectively during its most recent financial year – while the pace of progress across the group is quickening. The company is known for its pioneering Parsortix cell separation system which captures and then harvests circulating tumour cells (CTCs) from blood. Next steps include work on a large scale study to establish Parsortix as a diagnostic tool, enabling clinicians to choose the most appropriate treatment thereby improving patient outcomes.
We are delighted to announce that we have agreed a collaboration with a subsidiary of a large pharmaceutical company (the “Collaborator”) to investigate the combination of our Parsortix circulating tumour cell (CTC) harvesting platform with our Collaborator’s single cell analysis system.
Andrew Newland, chief executive of Angle plc (LON:AGL), tells Proactive investors that the company is now expanding the market it is targeting for Parsortix, its blood separation technology. Andrew also says that Angle is ‘close’ to achieving US Food & Drug Administration (FDA) approval.
Andrew Newland, CEO of Angle plc (LON:AGL), tells Proactive Investors that the company has achieved a “major breakthrough” in the potential use of its Parsortix non-invasive cancer diagnostic product. Andrew discusses what it means for the company and what investors should now watch out for.